Mithra Pharmaceuticals S.A.
MITPF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.09 | -0.40 | -0.03 |
| FCF Yield | -0.52% | -29.86% | -11.76% | -16.24% |
| EV / EBITDA | -11.85 | 30.17 | -13.59 | -10.01 |
| Quality | ||||
| ROIC | -34.46% | -38.51% | -21.61% | -14.90% |
| Gross Margin | 14.92% | 52.89% | -15.36% | -47.62% |
| Cash Conversion Ratio | 0.01 | 1.12 | 0.74 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | 21.00% | 95.04% | -38.30% | -46.17% |
| Free Cash Flow Growth | 97.63% | 13.97% | -7.59% | -52.07% |
| Safety | ||||
| Net Debt / EBITDA | -3.85 | 12.46 | -2.50 | -2.36 |
| Interest Coverage | -3.03 | -1.96 | -7.65 | -25.34 |
| Efficiency | ||||
| Inventory Turnover | 0.71 | 0.63 | 0.60 | 0.38 |
| Cash Conversion Cycle | 212.87 | 513.82 | 652.34 | 2,624.29 |